State University of New York Upstate Medical University

Adiso Therapeutics Expands Board of Directors with Appointment of Robert Lisicki

Retrieved on: 
Thursday, October 12, 2023
Acquisition, UC, Amgen, Regeneron Pharmaceuticals, Inflammation, Trial of the century, IBD, Strategic planning, State university system, BS, Inflammatory bowel disease, Arena Pharmaceuticals, Transgene (company), Ulcerative colitis, Therapy, Immunology, JNJ, Janssen Pharmaceuticals, State University of New York Upstate Medical University, Economics, Pfizer, MRP2, Patient, Neutrophil, Pharmaceutical industry, Circulatory system, Pain

CONCORD, Mass., Oct. 12, 2023 /PRNewswire/ -- Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, today announced the appointment of Robert Lisicki to the Company's Board of Directors.

Key Points: 
  • CONCORD, Mass., Oct. 12, 2023 /PRNewswire/ -- Adiso Therapeutics, Inc., a clinical-stage biotechnology company committed to creating medicines that treat inflammatory diseases and improve the lives of patients and their families, today announced the appointment of Robert Lisicki to the Company's Board of Directors.
  • "The Adiso Board and I are very pleased to welcome Robert Lisicki.
  • Rob is an accomplished biopharma industry executive, with multiple drug approvals to his credit, and his appointment is a welcome addition," said Jason Dinges, Morningside Technology Advisory and Adiso Board Member.
  • Mr. Lisicki has nearly 30 years of experience in the pharma/biotech sector, most recently serving as Chief Executive Office and Board Member of InCarda Therapeutics.

Supernus Announces New Qelbree® Data Showing Improvement in ADHD Symptoms

Retrieved on: 
Sunday, September 10, 2023
Blood pressure, Psych, MAOI, Fatigue, Research and development, Central nervous system, Depression, Senior, AE, Mania, State University of New York Upstate Medical University, Xerostomia, Aes, ADHD, Trae tha Truth, Constipation, Medicine, Appetite, CNS, OLE, AISRS, Vomiting, Administration, Insomnia, Vital signs, Patient, Child, Boxed warning, Psychiatry, Theophylline, Nausea, Somnolence, Behavioral medicine, Heart rate, Upper respiratory tract infection, FDA, Headache, Function (mathematics), Irritability, Bipolar disorder, Food, Safety, Dietary supplement, Birth control, Pharmaceutical industry, Copper, Residential care, Viloxazine

Results showed significant symptom improvement from baseline ADHD-RS-5 and CGI-S scores following both morning and evening dosing of Qelbree in combination with the morning psychostimulant.

Key Points: 
  • Results showed significant symptom improvement from baseline ADHD-RS-5 and CGI-S scores following both morning and evening dosing of Qelbree in combination with the morning psychostimulant.
  • “These data demonstrate Qelbree’s ability to enhance efficacy when co-administered with stimulants, including significant improvement during evening hours when the effects of stimulants often wear off following their morning dose.
  • Patients ADHD symptoms improved from 37.9 (6.34) to 19.7 (12.16) on the Adult ADHD Investigator Symptom Rating Scale (AISRS), representing average symptom reduction of -18.2 (11.54).
  • Patients executive function improved from 70.4 (10.94) to 58.3 (16.19) on the BRIEF-A Global Executive Composite scale, representing improvement in executive function of -12.9 (13.48).

Nexcella Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board

Retrieved on: 
Friday, August 18, 2023
University, State University of New York Upstate Medical University, Nanakaly Hospital for Hematology & Oncology, Hematology, Multiple myeloma, AL amyloidosis, Bone marrow, University of Colorado, Transplant, Memorial Sloan Kettering Cancer Center, AL, Patient, Memorial, Amyloidosis, Internal medicine, MSK, LOS, Dentistry

Dr. Landau brings extensive experience in designing clinical trials in hematology and oncology, novel treatment approaches for AL amyloidosis and multiple myeloma, and thought leadership to Nexcella.

Key Points: 
  • Dr. Landau brings extensive experience in designing clinical trials in hematology and oncology, novel treatment approaches for AL amyloidosis and multiple myeloma, and thought leadership to Nexcella.
  • “Patients with relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma deserve more effective treatments that can improve their outcomes,” said Dr. Landau.
  • I am excited to join the Nexcella Scientific Advisory Board and help advance NXC-201 for U.S. patients with AL Amyloidosis and multiple myeloma.”
    "We are delighted to have Dr. Landau join the Nexcella Scientific Advisory Board," stated Ilya Rachman, Executive Chairman of Nexcella.
  • We are excited to be collaborating with Dr. Landau.”
    Dr. Heather Landau is the Director of Amyloidosis Program and a Bone Marrow Transplant Specialist & Cellular Therapist at Memorial Sloan-Kettering Cancer Center in New York.

Immix Biopharma Announces Dr. Heather Landau, Memorial Sloan Kettering Cancer Center Amyloidosis Program Director, Joins Nexcella Scientific Advisory Board

Retrieved on: 
Friday, August 18, 2023
University, State University of New York Upstate Medical University, Nanakaly Hospital for Hematology & Oncology, Hematology, Multiple myeloma, AL amyloidosis, Bone marrow, University of Colorado, Transplant, Memorial Sloan Kettering Cancer Center, AL, Patient, Memorial, Amyloidosis, Internal medicine, MSK, LOS, Dentistry

Dr. Landau brings extensive experience in designing clinical trials in hematology and oncology, novel treatment approaches for AL amyloidosis and multiple myeloma, and thought leadership to Nexcella.

Key Points: 
  • Dr. Landau brings extensive experience in designing clinical trials in hematology and oncology, novel treatment approaches for AL amyloidosis and multiple myeloma, and thought leadership to Nexcella.
  • “Patients with relapsed/refractory AL amyloidosis and relapsed/refractory multiple myeloma deserve more effective treatments that can improve their outcomes,” said Dr. Landau.
  • I am excited to join the Nexcella Scientific Advisory Board and help advance NXC-201 for U.S. patients with AL Amyloidosis and multiple myeloma.”
    "We are delighted to have Dr. Landau join the Nexcella Scientific Advisory Board," stated Ilya Rachman, Chief Executive Officer of Immix Biopharma.
  • We are excited to be collaborating with Dr. Landau.”
    Dr. Heather Landau is the Director of Amyloidosis Program and a Bone Marrow Transplant Specialist & Cellular Therapist at Memorial Sloan-Kettering Cancer Center in New York.

Singular Genomics Appoints Genomics Veteran Marcia Eisenberg, Ph.D., to Board of Directors

Retrieved on: 
Tuesday, August 8, 2023
Singular, DNA, Enterprise, National Institute of Environmental Health Sciences, University, Senior, Doctor of Philosophy, State University of New York Upstate Medical University, Genomics, Health care, Biotechnology, NGS, State university system, LH, Lead, OMIC, Molecular biology, Fierce, Polymerase chain reaction, SAN, Medicine, Growth, Federal Bureau of Investigation, Health, Labcorp, Woman, NYSE, PCR, Management, Psychology, Biology

SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Marcia Eisenberg, Ph.D., to the Company’s Board of Directors.

Key Points: 
  • SAN DIEGO, Aug. 08, 2023 (GLOBE NEWSWIRE) -- Singular Genomics Systems, Inc. (Nasdaq: OMIC), a company leveraging novel next-generation sequencing (NGS) and multiomics technologies to empower researchers and clinicians, today announced the appointment of Marcia Eisenberg, Ph.D., to the Company’s Board of Directors.
  • “Marcia’s deep and diverse genomics expertise will be an asset to Singular as we drive our business strategy forward, and we are delighted to welcome her to the Board of Directors,” said Drew Spaventa, Chairman and Chief Executive Officer of Singular Genomics.
  • She served in a variety of other roles at Labcorp and its affiliates starting in 1990.
  • “I have been impressed by Singular Genomics’ growth and progress in launching a sequencing platform that I believe is uniquely positioned to positively impact many critical applications,” said Dr. Eisenberg.

You're Not Going to Believe This: Blueprint Prep Just Made Its Study App Free for Every Med Student

Retrieved on: 
Thursday, August 3, 2023
Workforce, Medicine, USMLE, Partnership, Student, Blueprint, Physician, Entrepreneurship, LOS, Hand, Nursing, Tutoring, State University of New York Upstate Medical University

LOS ANGELES, Aug. 3, 2023 /PRNewswire/ -- Blueprint Prep, the leading platform for innovative test prep and tutoring solutions, recently announced that it would offer its customizable study planner Blueprint's Med School Study Planner, formerly known as Cram Fighter, to every medical student in the nation, free of charge. The bold initiative follows a partnership Blueprint Prep formed with ten medical schools — including USC Keck, SUNY Upstate, San Juan Bautista, and PONCE — that allowed their students to use Blueprint's Med School Study Planner for free.

Key Points: 
  • LOS ANGELES, Aug. 3, 2023 /PRNewswire/ -- Blueprint Prep , the leading platform for innovative test prep and tutoring solutions, recently announced that it would offer its customizable study planner Blueprint's Med School Study Planner, formerly known as Cram Fighter, to every medical student in the nation, free of charge.
  • The bold initiative follows a partnership Blueprint Prep formed with ten medical schools — including USC Keck, SUNY Upstate, San Juan Bautista, and PONCE — that allowed their students to use Blueprint's Med School Study Planner for free.
  • Blueprint's Med School Study Planner is exactly what I needed to make my dedicated study schedule," said one student.
  • To learn more about Blueprint's Med School Study Planner, formerly known as Cram Fighter, features and to read student reviews, visit https://blueprintprep.com/medical/med-school/study-schedule .

Zentalis Pharmaceuticals Appoints Kimberly Freeman as Chief Strategy Officer

Retrieved on: 
Tuesday, August 1, 2023
DNA, GSK plc, Drug development, Cyclin, Female, Therapy, University, DDR, ARM, Cancer, Medication, Postgraduate education, Weill Cornell Medical Center, AstraZeneca, Marketing, Reliance Institute of Life Sciences, Boehringer Ingelheim, Regenerative medicine, Wharton School of the University of Pennsylvania, Graduate, Patient, SAN, State University of New York Upstate Medical University, Cell, Clinical Ovarian Cancer & Other Gynecologic Malignancies, Commodity, Research, FDA, Woman, Cornell University, Widener University Commonwealth Law School, Pharmaceutical industry, Medical imaging, Science, Biology

NEW YORK and SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Kimberly Freeman as Chief Strategy Officer.

Key Points: 
  • NEW YORK and SAN DIEGO, Aug. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced the appointment of Kimberly Freeman as Chief Strategy Officer.
  • In this role, she will support and implement Zentalis’ long-term portfolio strategy.
  • Ms. Freeman joins Zentalis with over 25 years of clinical development and strategic leadership experience, including deep expertise in oncology, particularly in gynecologic malignancies and the DNA damage response (DDR) pathway.
  • “Kimberly brings an outstanding track record of building and executing drug development and franchise strategies that will be invaluable to Zentalis as we seek to capitalize on the significant opportunity we see with azenosertib across a broad array of tumor types,” said Dr. Kimberly Blackwell, Chief Executive Officer of Zentalis.

UnitedHealthcare Donates $1.5 Million To Nine Nonprofit Organizations in New York

Retrieved on: 
Tuesday, July 25, 2023
Men, Managed Care, Professional Services, Family, Philanthropy, Consumer, Fund Raising, Health Insurance, Foundation, Women, Insurance, Health, American Journal of Preventive Medicine, Food, Housing, University, Health education, Community, Case management (US healthcare system), Prenatal care, Health equity, Woman, Preventive healthcare, State University of New York Upstate Medical University, University of Rochester Medical Center, Mindfulness, American Medical Association, NYSE, UNH, Immigration, Student, American Journal, Home, Patient, Social isolation, Refugee, CAMBA, Inc., RISE, Optum, Transport, Mental health, Environment, Counselor, Central New York, Nursing, Pharmaceutical industry, UnitedHealth Group

In total, UnitedHealthcare is donating more than $11.1 million in grants through its Empowering Health program across 12 states.

Key Points: 
  • In total, UnitedHealthcare is donating more than $11.1 million in grants through its Empowering Health program across 12 states.
  • “UnitedHealthcare is honored to support the important work these local organizations are doing to provide greater access to services for underserved communities in New York,” said Junior Harewood, CEO, UnitedHealthcare of New York.
  • Identifying and addressing social determinants of health needs is a core aspect of how UnitedHealthcare serves its members.
  • Since launching its Empowering Health commitment in 2018, UnitedHealthcare has now invested more than $62 million in Empowering Health grants, reaching nearly 11 million people through partnerships with community-based organizations in 30 states and the District of Columbia.

Practical Pain Management and Society of Pain & Palliative Care Pharmacists Foundation Announce Second Annual Fudin Award for Mentorship

Retrieved on: 
Thursday, July 6, 2023
Lewis & Clark College, Society, Doctor of Pharmacy, University, McPherson, Education, PPM, Outcomes research, State University of New York Upstate Medical University, Mentorship, Patient, Medicine, Doctor of Philosophy, Maryland School, Pain, Pharmacist, Student, Professor, Stratton, Trustee, Humour, Outline of health sciences, Pain management, Education minister, FCCP, Albany College of Pharmacy and Health Sciences, American Cancer Society, Knowledge, Chronic pain, Memory, Nursing, Medical device, Pharmacy, Palliative care

ARLINGTON, Va., July 6, 2023 /PRNewswire/ -- Practical Pain Management (PPM), a leading digital health brand serving  pain-treating clinicians, and the Society of Pain and Palliative Care Pharmacists Foundation, today announced that Mary Lynn McPherson, PhD, PharmD, has been awarded the Fudin Award for Mentorship.

Key Points: 
  • ARLINGTON, Va., July 6, 2023 /PRNewswire/ -- Practical Pain Management (PPM), a leading digital health brand serving  pain-treating clinicians, and the Society of Pain and Palliative Care Pharmacists Foundation, today announced that Mary Lynn McPherson, PhD, PharmD, has been awarded the Fudin Award for Mentorship.
  • "Her work demonstrates her dedication to the advancement of palliative care, inspiring students to follow in her footsteps," said Dr. Jeff Gudin, PPM editor-at-large.
  • For decades, she has educated on pain management and palliative care at both local and national levels.
  • Dr. Fudin was a founding member and inaugural Trustee for the Society of Pain and Palliative Care Pharmacists and he was co-editor of PPM.

Susan M. Love, MD, MBA, Chief Visionary Officer and "Founding Mother" of Breast Cancer Advocacy and Research Dies

Retrieved on: 
Monday, July 3, 2023
President Clinton, Volunteering, Love, Executive, Surgeon, Fordham University, University, Army, Brigham and Women's Faulkner Hospital, Parent, State university system, Radiology, National Breast Cancer Coalition, Anderson School, Marriage, Woman, MBA, Research, History, Alpha Omega Alpha, Young Survival Coalition, Movement, HRT, NBCC, SUNY Downstate Medical Center, Beth Israel Hospital, International Symposium on Endovascular Therapy, MD, Breast cancer, The New York Times, Patient, Notre Dame, Revlon, Breast, Supreme court, School Sisters of Notre Dame, LOS, AI, Oncology, UCLA, State University of New York Upstate Medical University, Leukemia, Mammography, NIH, Hormone replacement therapy, Birth control, Medical device

LOS ANGELES, July 3, 2023 /PRNewswire/ -- Susan M. Love, MD, MBA, who led Dr. Susan Love Foundation for Breast Cancer Research since 1995, steering the Foundation through its innovative and life-changing research and advocacy programs, has died. She was 75.

Key Points: 
  • She was an early advocate of cancer surgery that conserves as much breast tissue as possible.
  • A founder of the breast cancer advocacy movement in the early 1990's, she helped organize the National Breast Cancer Coalition (NBCC) .
  • As Founder and Chief Visionary Officer of the Dr. Susan Love Foundation for Breast Cancer Research, Dr. Love built and oversaw an active research program centered on the cause and prevention of breast cancer.
  • The Love Research Army, which she launched in 2008, creatively accelerated cancer research by partnering volunteers and scientists for clinical trials and cancer research.